On Tuesday, YPF SA (ADR) (NYSE:YPF)’s shares inclined 1.87%, and closed at $29.91, after YPF (YPF), declared the results of its offer to exchange any and all of its outstanding 10% Medium-Term Notes (Series C) due 2028 (the “Old Notes”) for 8.875% Senior Notes due 2028 (the “New Notes”).
YPF issued the original 8.875% Senior Notes due 2018, which have the same terms as the New Notes and will be fully fungible with the New Notes, in a principal amount of U.S.$500,000,000 on December 19, 2013. The aggregate principal amount of New Notes issued in exchange for Old Notes tendered in the exchange offer will be (i) raised by accrued and unpaid interest on the Old Notes, and then (ii) reduced by interest accrued on such New Notes from December 19, 2013 (as if they had been issued together with the Original 2018 Notes) up to but not including the Settlement Date, calculated based on the aggregate principal amount of Old Notes tendered. The total amount of New Notes to be issued to any tendering holder of Old Notes will be rounded down to the nearest U.S.$1,000. YPF will pay any fractional portion of the New Notes not received as a result of rounding down in cash. Interest on the New Notes will accrue from December 19, 2013.
YPF Sociedad Anónima, an energy corporation, operates in the upstream and downstream activities in Argentina. It engages in the exploration, development, and production of crude oil, natural gas, and liquefied petroleum gas (LPG).
Mylan NV (NASDAQ:MYL)’s shares raised 1.86%, and settled at $59.57, during the last trading session on Tuesday, as Mylan NV (MYL), declared the U.S. introduce of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable), which is the generic version of Warner Chilcott’s Generess® Fe Tablets. Mylan’s partner Famy Care Ltd. received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for this product, which is indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception.(1) Mylan’s immediate shipment of Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable) represents the corporation’s ninth oral contraceptive product launch in the U.S.
Norethindrone and Ethinyl Estradiol Tablets (Chewable) 0.8 mg/0.025 mg and Ferrous Fumarate Tablets, 75 mg (Chewable) had U.S. sales of about $114.7 million for the 12 months ending December 31, 2014, according to IMS Health.
Mylan N.V., through its auxiliaries, develops, licenses, manufactures, markets, and distributes generic, branded generic, and specialty pharmaceuticals worldwide. The corporation provides generic or branded generic pharmaceutical products in tablet, capsule, injectable, or transdermal patch forms, in addition to active pharmaceutical ingredients (APIs).
At the end of Tuesday’s trade, FXCM Inc (NYSE:FXCM)’s shares picked up 1.86%, and closed at $2.19, after FXCM Inc (FXCM), declared that it has repaid an additional $54 million outstanding under its credit contract with Leucadia. The payment was funded in part with proceeds from the sale of FXCM Japan. FXCM has now repaid $66 million under the credit contract, and as of April 1, 2015, FXCM’s outstanding Leucadia loan balance is $244 million.
By repaying more than $60 million before April 16, 2015, FXCM has avoided a contingent financing fee of $30 million, and FXCM shareholders stand to benefit from an improved sharing determination of proceeds from future asset sales, dividends and distributions following the terms of the credit contract.
“FXCM is happy with how our debt reduction plan is proceeding,” said Drew Niv, CEO of FXCM. “We are ahead of plan and the results of the FXCM Japan sale exceeded our expectations. With all the raised attention to our other properties, we are expecting robust and competitive auctions for the other non-core assets we have targeted to sell.”
FXCM Inc., through its subsidiaries, provides online foreign exchange (FX) trading and related services to retail and institutional customers worldwide. The company operates in two segments, Retail Trading and Institutional Trading. It acts as an agent between retail customers and a collection of global banks and financial institutions by making foreign currency markets for customers trading in foreign exchange spot markets.
Take-Two Interactive Software, Inc (NASDAQ:TTWO), ended its Tuesday’s trading session with 1.07% gained, and closed at $25.14, soon after Take-Two Interactive Software, (TTWO), declared the first simulation-based WWE video game for mobile platforms, WWE® 2K, is in development for iOS and Android devices. Presently planned for release in spring 2015 at a price point of $7.99, WWE 2K will offer authentic WWE gameplay in a mobile format through inspiration from several popular gameplay elements and modes from the WWE 2K flagship WWE video game franchise accessible on consoles.
Key features of WWE 2K presently comprise:
- Playable roster of many fan-favorite WWE Superstars, counting John Cena®, Hulk Hogan®, Sting®, Triple H®, Undertaker®, Daniel Bryan®, Roman Reigns™, Seth Rollins™, Dean Ambrose™ and Bray Wyatt™;
- Authentic WWE action, counting three match types, full WWE Superstar ring entrances and comprehensive move sets;
- Create-a-Superstar;
- Career Mode;
- Live Multiplayer Matches;
- Unlockable Rewards.
Take-Two Interactive Software, Inc. develops, publishes, and markets interactive entertainment for consumers worldwide. The corporation offers its products under the Rockstar Games and 2K labels. It develops and publishes action/adventure products under the Grand Theft Auto, Max Payne, Midnight Club, and Red Dead names through developing sequels, offering downloadable episodes and content, and releasing titles for smartphones and tablets.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
